These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 29908231)

  • 21. Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma.
    Mariotti J; Devillier R; Bramanti S; Giordano L; Sarina B; Furst S; Granata A; Maisano V; Pagliardini T; De Philippis C; Kogan M; Faucher C; Harbi S; Chabannon C; Carlo-Stella C; Bouabdallah R; Santoro A; Blaise D; Castagna L
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1810-1817. PubMed ID: 31128326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors.
    Nakamae H; Fujii K; Nanno S; Okamura H; Nakane T; Koh H; Nakashima Y; Nakamae M; Hirose A; Teshima T; Hino M
    Transpl Int; 2019 Dec; 32(12):1322-1332. PubMed ID: 31432532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
    Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.
    Elmariah H; Kasamon YL; Zahurak M; Macfarlane KW; Tucker N; Rosner GL; Bolaños-Meade J; Fuchs EJ; Wagner-Johnston N; Swinnen LJ; Huff CA; Matsui WH; Gladstone DE; McCurdy SR; Borrello I; Gocke CB; Shanbhag S; Cooke KR; Ali SA; Brodsky RA; DeZern AE; Luznik L; Jones RJ; Ambinder RF
    Biol Blood Marrow Transplant; 2018 May; 24(5):1099-1102. PubMed ID: 29452245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous graft-versus-host disease incidence is similar in haploidentical and matched unrelated hematopoietic transplant recipients: A retrospective cohort study.
    Heberton MM; Tripathi S; Slade M; Trinkaus K; Romee R; Anadkat M
    J Am Acad Dermatol; 2020 Dec; 83(6):1654-1658. PubMed ID: 31689447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH).
    Pérez-Martínez A; Ferreras C; Pascual A; Gonzalez-Vicent M; Alonso L; Badell I; Fernández Navarro JM; Regueiro A; Plaza M; Pérez Hurtado JM; Benito A; Beléndez C; Couselo JM; Fuster JL; Díaz-Almirón M; Bueno D; Mozo Y; Marsal J; Gómez López A; Sisinni L; de Heredia CD; Díaz MÁ
    Am J Hematol; 2020 Jan; 95(1):28-37. PubMed ID: 31625177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
    Gayoso J; Balsalobre P; Kwon M; Herrera P; Bermúdez A; Sampol A; Jiménez S; López-Corral L; Serrano D; Piñana JL; Pascual MJ; Heras I; Bento L; Varela R; Humala K; Zabalza A; Laiglesia A; Bastos-Oreiro M; Pérez-Corral A; Martínez-Laperche C; Buño I; Díez-Martín JL;
    Eur J Haematol; 2018 Sep; 101(3):332-339. PubMed ID: 29846964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.
    Munchel AT; Kasamon YL; Fuchs EJ
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):359-68. PubMed ID: 21925089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor's age influences outcome in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide - a single center experience.
    Zielińska P; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Gruenpeter K; Kopińska A; Woźniczka K; Noster I; Gromek T; Czyż J; Grosicki S; Wierzbowska A; Krzanowski J; Butrym A; Helbig G
    Ann Hematol; 2024 Aug; 103(8):3095-3104. PubMed ID: 38878171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
    Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.
    Kasamon YL; Bolaños-Meade J; Prince GT; Tsai HL; McCurdy SR; Kanakry JA; Rosner GL; Brodsky RA; Perica K; Smith BD; Gladstone DE; Swinnen LJ; Showel MM; Matsui WH; Huff CA; Borrello I; Pratz KW; McDevitt MA; Gojo I; Dezern AE; Shanbhag S; Levis MJ; Luznik L; Ambinder RF; Fuchs EJ; Jones RJ
    J Clin Oncol; 2015 Oct; 33(28):3152-61. PubMed ID: 26261255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.
    Blaise D; Fürst S; Crocchiolo R; El-Cheikh J; Granata A; Harbi S; Bouabdallah R; Devillier R; Bramanti S; Lemarie C; Picard C; Chabannon C; Weiller PJ; Faucher C; Mohty B; Vey N; Castagna L
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):119-24. PubMed ID: 26341397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.
    Duléry R; Ménard AL; Chantepie S; El-Cheikh J; François S; Delage J; Giannotti F; Ruggeri A; Brissot E; Battipaglia G; Malard F; Belhocine R; Sestili S; Vekhoff A; Delhommeau F; Reman O; Legrand O; Labopin M; Rubio MT; Mohty M
    Biol Blood Marrow Transplant; 2018 May; 24(5):1013-1021. PubMed ID: 29337223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML.
    Rashidi A; Slade M; DiPersio JF; Westervelt P; Vij R; Romee R
    Bone Marrow Transplant; 2016 Dec; 51(12):1561-1564. PubMed ID: 27526282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
    Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
    Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
    J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haploidentical hematopoietic stem cell transplantation in children with high-risk hematologic malignancies: outcomes with two different strategies for GvHD prevention. Ex vivo T-cell depletion and post-transplant cyclophosphamide: 10 years of experience at a single center.
    Dufort G; Castillo L; Pisano S; Castiglioni M; Carolina P; Andrea I; Simon E; Zuccolo S; Schelotto M; Morosini F; Pereira I; Amarillo P; Silveira A; Guerrero L; Ferreira V; Tiscornia A; Mezzano R; Lemos F; Boggia B; Quarnetti A; Decaro J; Dabezies A
    Bone Marrow Transplant; 2016 Oct; 51(10):1354-1360. PubMed ID: 27272446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders.
    Klein OR; Chen AR; Gamper C; Loeb D; Zambidis E; Llosa N; Huo J; Dezern AE; Steppan D; Robey N; Holuba MJ; Cooke KR; Symons HJ
    Biol Blood Marrow Transplant; 2016 May; 22(5):895-901. PubMed ID: 26860634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
    Luznik L; O'Donnell PV; Symons HJ; Chen AR; Leffell MS; Zahurak M; Gooley TA; Piantadosi S; Kaup M; Ambinder RF; Huff CA; Matsui W; Bolaños-Meade J; Borrello I; Powell JD; Harrington E; Warnock S; Flowers M; Brodsky RA; Sandmaier BM; Storb RF; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):641-50. PubMed ID: 18489989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.